Heptares Overview

  • Year Founded
  • 2007

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 75

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $5M

  • Investors
  • 1

Heptares General Information

Description

Developer of a novel drug designed to target G protein-coupled receptors. The company's drugs have the potential to transform the treatment of Alzheimer's disease, ADHD, diabetes, schizophrenia, migraine, and other diseases, enabling physicians to treat critical diseases.

Contact Information

Website
www.heptares.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Acquirer
Sosei
Primary Office
  • Granta Park
  • Great Abington
  • Cambridge CB21 6GP
  • England, United Kingdom

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Heptares Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC 18-May-2017 $5M 000 Completed Generating Revenue
6. Grant 28-Sep-2015 00.00 Completed Generating Revenue
5. Merger/Acquisition 23-Feb-2015 00000 000.00 00000 Completed Generating Revenue
4. Later Stage VC (Series B) 27-Jun-2013 0000 000.00 Completed Generating Revenue
3. Early Stage VC (Series A) 24-Feb-2009 000.00 000.00 000.00 Completed Generating Revenue
2. Seed Round 13-Aug-2007 Completed Startup
1. Spin-Off 04-Jun-2007 Completed Startup
To view Heptares’s complete valuation and funding history, request access »

Heptares Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series A 00,000,000 00.000000 00.00 00.00 00 00.00 00.000
To view Heptares’s complete cap table history, request access »

Heptares Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a novel drug designed to target G protein-coupled receptors. The company's drugs have the potential to tran
Drug Discovery
Cambridge, United Kingdom
75 As of 2014
000
0000000000 0 000

000000

r incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nos
0000 000000000
Boston, MA
00 As of 0000
00000
000000000 00000

0000 0

lore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, s
0000000000000
Stamford, CT
00 As of 0000
00000
0.000 0000-00-00
000000&0 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Heptares Competitors (132)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Compass Therapeutics Formerly VC-backed Boston, MA 00 00000 000000000 00000
0000 00000000 Formerly VC-backed Stamford, CT 00 00000 000000&0 00000
000000 Venture Capital-Backed Lebanon, NH 000 00000 0000000000 0 00000
00000 000000000000 Venture Capital-Backed Ghent, Belgium 00 000.00 0000000000 000.00
0000000 000000 Formerly VC-backed Lyon, France 00 00000 00000000 00000
You’re viewing 5 of 132 competitors. Get the full list »

Heptares Patents

  • 711

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 40

    Granted

  • 32

    Pending

  • 000

    Expiring in next 12 mo

Heptares Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-202309615-D0 Muscarinic receptor agonists Pending 26-Jun-2023
GB-202305444-D0 Muscarinic receptor agonists Pending 13-Apr-2023
GB-202214644-D0 Sars-cov-2 mpro inhibitors and uses thereof Pending 05-Oct-2022
GB-202211483-D0 Pharmaceutical combination products Inactive 05-Aug-2022
GB-202211474-D0 Methods of synthesis Inactive 05-Aug-2022
To view Heptares’s complete patent history, request access »

Heptares Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Heptares Former Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Blackstone Life Sciences PE/Buyout Minority 000 0000 000000 0
MVM Partners Growth/Expansion Minority 000 0000 000000 0
Novartis Venture Fund Corporate Venture Capital 000 0000 000000 0
Omega Funds Venture Capital Minority 000 0000 000000 0
Stanley Family Foundation Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 7 investors. Get the full list »

Heptares Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
G7 Therapeutic 30-Nov-2016 0000000000 0000 Biotechnology 00000 000
To view Heptares’s complete acquisitions history, request access »

Ready to get started?

Request a free trial